Home
Clinical Trials
Study In Patients With Depres...

Study In Patients With Depression Not Responding to Selective Serotonin Re-uptake Inhibitors

Last Updated: 2019-12-04

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

325 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-01-19

Study Completion Date

2008-03-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is designed to evaluate the efficacy and safety in depressive patients who did not respond sufficiently to selective serotonin re-uptake inhibitors (SSRI).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Effects of Wellbutrin (Bupropion) on Residual and Cognitive Symptoms in SSRI-treated Depression

NCT00125957

Depression Major Depressive Disorder Unipolar Depression

COMPLETED PHASE3

Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms

NCT06559306

Depressive Disorder, Major

RECRUITING PHASE3

Study of Fluoxetine in Adults With Autistic Disorder

NCT00027404

Autistic Disorder

COMPLETED NA

Study of 6(S)-5-MTHF Among Selective Serotonin Reuptake Inhibitor-Resistant Outpatients With Major Depressive Disorder

NCT00955955

Depression

COMPLETED PHASE4

Treatment of Post-Traumatic Brain Injury (TBI) Depression

NCT00233103

Depression

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Depressive Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Placebo

Subjects with Major Depressive Disorder who were randomised to placebo to match Bupropion SR during the treatment period.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Subjects with Major Depressive Disorder who were randomised to placebo to match Bupropion SR during the treatment period.

Bupropion SR

Subjects with Major Depressive Disorder who were randomized to take 100mg of Bupropion SR in the morning and placebo in the evening for one week. Week 2 subjects were given 100mg dose of Bupropion morning and evening. Weeks 3 thru 12 received 150mg dose morning and evening. Week 1=dose level 1, 100 mg. Week 2=dose level 2, 200 mg. Weeks 3 - 12=dose level 3, 300 mg.

Group Type EXPERIMENTAL

323U66 (Bupropion Hydrochloride Sustained Release)

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

323U66 (Bupropion Hydrochloride Sustained Release)

Intervention Type DRUG

Placebo

Subjects with Major Depressive Disorder who were randomised to placebo to match Bupropion SR during the treatment period.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* \[At the start of the pretreatment phase\]
* Target disease: Patients diagnosed as having the following primary disease on the basis of DSM-IV-TR criteria.
* Major Depressive Disorder, Single Episode (296.2x) (excluding with psychotic features)
* Major Depressive Disorder, Recurrent (296.3x) (excluding with psychotic features)
* HAM-D (17 items) total score is \>=16.
* Patients who have been treated with marketed paroxetine (Paxil®) at 20mg/day to 40mg/day for 4 weeks and more at the start of the pretreatment phase.
* Age: \>=18 years old (at the time of informed consent) , \<65 years old (at the start of treatment phase )
* Gender: Male or female.
* Inpatients or outpatients: Either
* Informed consent: The subject himself/herself must give written informed consent. However, if the subject is under 20 at the time of giving consent, both the subject himself/herself and his/her legally acceptable representative must give written informed consent.

\[At the end of the pretreatment phase\]

1. HAM-D (17 items) total score is ≥14.
2. Percentage of change from the start of the pretreatment phase in the HAM-D (17 items) total score is \<50%

\[At the start of the treatment phase\]

1. HAM-D (17 items) total score is ≥14.
2. Percentage of change from the start of the pretreatment phase in the HAM-D (17 items) total score is \<50%

Exclusion Criteria

\[At the start of the pre-treatment phase\]

* Patients with a complication of glaucoma
* Patients concomitantly using a drug increasing the risk of bleeding and patients with bleeding tendency or predisposition to bleeding
* Patients with predisposition to seizure (who currently have or have a past history of seizure, febrile convulsive seizure in infancy, cerebral tumour, cerebrovascular disorder or head injury, who have a family history of idiopathic seizure, patients with diabetes who have been treated with oral hypoglycaemics or insulin, or who use drugs lowering the threshold of seizure).
* Patients who currently have or have a past history of the following disorders:
* Anorexia nervosa (DSM-IV-TR 307.1)
* Bulimia nervosa (DSM-IV-TR 307.51)
* Patients with a history of manic episode
* Patients with a past or current DSM- IV-TR diagnosis of schizophrenia or other psychotic disorder
* Patients with a current DSM-IV-TR Axis II diagnosis (e.g., antisocial or borderline personality disorder)
* Patients starting psychotherapy (except for supportive psychotherapy not aimed at therapeutic efficacy and unlikely to affect efficacy evaluation) and formal cognitive behaviour therapy within 5 weeks prior to the start of the pre-treatment phase
* Patients with a diagnosis of substance abuse (alcohol or drug) by the DSM-IV-TR criteria or with a diagnosis of substance dependence within 1 year prior to the start of the pre-treatment phase
* Patients who have received electroconvulsive therapy within 17 weeks prior to the start of the pre-treatment phase
* Patients who have taken MAO inhibitors (selegiline hydrochloride) within 2 weeks prior to the start of the pre-treatment phase
* Patients who have taken another investigational drug within 12 weeks prior to the start of the pre-treatment phase
* Female patients who are pregnant, possibly pregnant or are nursing, and those who want to become pregnant before 30 days after the last dose of the investigational product
* Patients who have attempted suicide within 17 weeks prior to the start of the pre-treatment phase, or patients for whom the score of suicide-related item No. 3 of HAM-D is \>=3, or patients in whom the risk of suicide is judged to be high by the investigator (sub-investigator)
* Patients in whom the risk of homicide is judged to be high by the investigator (sub-investigator)
* Patients with a history of hypersensitivity to 323U66 and/or paroxetine
* Patients with serious cerebral disease
* Patients who have ECG or clinical evidence of any cardiac condition that the investigator (sub-investigator) feels may predispose the subject to ischemia or arrhythmia
* Patients with serious physical symptoms (i.e. cardiac/hepatic/renal disorder, hematopoietic disorder) The index of seriousness is Grade 3 of "Criteria for classification of seriousness of adverse drug reactions to pharmaceutical products, etc." (PAB/PSD No.80 in 1992).
* Patients with a history or complication of cancer or malignant tumour.
* Patients whose major depressive disorder is due to direct physiological effects of a general medical condition (for example, hypothyroidism, Parkinson's disease, chronic pain)
* Patients with systolic blood pressure of \>=160 mmHg or diastolic blood pressure of \>=100 mmHg
* Patients who are inappropriate for participating in the study in the judgement of the investigator (sub-investigator)

\[At the start of the treatment phase\]

1. Patients whose compliance of paroxetine during the pretreatment phase is less than 70%.
2. Patients who have ECG or clinical evidence of any cardiac condition that the investigator (sub-investigator) feels may predispose the subject to ischemia or arrhythmia
3. Patients with systolic blood pressure of \>=160 mmHg or diastolic blood pressure of \>=100 mmHg

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers